Theravance Biopharma : TBPH Q1 2025 Earnings Presentation vf

Published: 2025-05-08 20:08:40 ET TBPH

Published on 05/08/2025 at 20:08

First Quarter 2025 Financial Results and

Business Update

May 8, 2025

THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE®

are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

All third-party trademarks used herein are the property of their respective owners.

© 2025 Theravance Biopharma. All rights reserved.

Opening & Closing Remarks Rick Winningham: Chief Executive Officer

Commercial Updates Rhonda Farnum: Senior Vice President, Chief Business Officer

Development & Regulatory Updates Dr. Áine Miller: Senior Vice President, Development

TRELEGY & Financial Updates Aziz Sawaf: Senior Vice President, Chief Financial Officer

3

Q&A Team

Ampreloxetine TRELEGY / Corporate

Q1 net sales of $58.3M increased 6% Y/Y1

Customer demand increased 5% Y/Y2

Hospital performance remained strong,

with Q1 doses up 48% Y/Y3

CYPRESS open label enrollment nearing

completion

Expect final patient to be enrolled by late summer

Top line data anticipated ~6 mo. later

Continued important clinical, regulatory and pre-launch preparations across the organization

2024 TRELEGY net sales reached $854M (+14% Y/Y), on pace to trigger 2025 milestone of $50M4

$131M in cash and no debt

Commitment to return excess capital to

shareholders

In the US, Viatris is leading the commercialization of YUPELRI, and Theravance Biopharma co-promotes the product under a profit and loss sharing arrangement (65% to Viatris; 35% to Theravance Biopharma).

Source: Viatris Customer Demand (Q1'25). 3. Source: IQVIA DDD, HDS, VA and Non-Reporting Hospital through Mar'25. 4. Source: GSK-reported Net Sales in USD. As of 3/31/25, Theravance stood to receive up to

4 $150 million in 2025 and 2026 TRELEGY sales milestones paid directly from Royalty Pharma (RP). Based on 2025 TRELEGY global net sales, a first payment of $25 million would be triggered should RP receive $260 million or more in royalty payments from GSK and a second payment of $25 million (for a total of $50 million) would be triggered should RP receive $295 million or more in royalty payments from GSK. Theravance

estimates that these thresholds will be met should TRELEGY global net sales reach $3.063 billion and $3.413 billion, respectively.

Co-promotion agreement with VIATRISTM (35% / 65% Profit Share)

COPD, chronic obstructive pulmonary disease; LAMA, long-acting muscarinic antagonist

Disclaimer

Theravance Biopharma Inc. published this content on May 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 08, 2025 at 22:26 UTC.